Farxiga (dapagliflozin) is not a diuretic, but it does cause your body to lose extra fluid in a way that resembles one. It belongs to a drug class called SGLT2 inhibitors, which work by blocking sugar reabsorption in the kidneys. That sugar ends up in your urine and pulls water along with it, creating what’s known as osmotic diuresis. The result can look and feel like taking a water pill, but the underlying mechanism is fundamentally different.
How Farxiga Actually Works
Your kidneys normally filter glucose out of your blood and then reabsorb most of it back into the bloodstream through a protein called SGLT2, located in the early part of your kidney’s filtering tubes. Farxiga blocks that protein, reducing the kidney’s ability to reclaim filtered sugar by roughly 30 to 50%. The excess glucose spills into your urine instead.
Here’s where the diuretic-like effect comes in: glucose molecules in the urine attract water through osmosis. The FDA’s prescribing information for Farxiga states directly that it “causes an osmotic diuresis, which may lead to a reduction in intravascular volume.” So while the drug’s primary job is to get rid of excess sugar, shedding extra fluid is a built-in secondary effect.
How This Differs From True Diuretics
Traditional diuretics, like furosemide (a loop diuretic) or hydrochlorothiazide (a thiazide), force your kidneys to excrete more sodium. Water follows the sodium out, and your blood volume drops. That sodium-driven water loss is the core mechanism of every standard water pill.
Farxiga takes a different route. It does reduce some sodium reabsorption and increases sodium delivery to later parts of the kidney’s filtering system, but research published in the Journal of the American College of Cardiology found something surprising: in heart failure patients, dapagliflozin had no meaningful effect on 24-hour sodium excretion. The increase in solutes leaving the body was almost entirely explained by glucose, not sodium. In other words, it’s the sugar pulling water out, not salt.
That distinction matters because the body responds differently to each type of fluid loss. The same JACC study showed that patients’ bodies activated water-conservation mechanisms that largely canceled out the expected increase in urine volume. The researchers estimated that adaptive water retention prevented roughly 750 mL per day of potential extra urine output. In practice, total urine volume didn’t significantly increase over the study period.
How Much Extra Fluid You Actually Lose
If you’re expecting the dramatic increase in bathroom trips that comes with a loop diuretic, Farxiga is considerably milder. In critically ill patients studied in the DEFENDER trial, dapagliflozin increased urine output by about 47 mL on day one, gradually rising to roughly 157 mL per day by day five. The overall average increase was around 94 mL per day, which is less than half a cup of extra urine.
Despite that modest fluid shift, Farxiga does lower blood pressure slightly. In the large DAPA-HF trial of heart failure patients, systolic blood pressure dropped by about 2.5 mmHg more than placebo within two weeks. That’s a small but real reduction, consistent with mild volume loss and vascular effects.
Volume Depletion Risk
Because Farxiga nudges your body toward losing fluid, there’s a small risk of dehydration-related side effects. In pooled data from 13 clinical studies, volume depletion events (including low blood pressure, dehydration, and reduced blood volume) occurred in 1.1% of people taking Farxiga compared to 0.7% on placebo. About half of those events happened in the first eight weeks, with roughly one in five occurring within just the first two weeks.
In the larger DECLARE-TIMI 58 trial, which followed patients longer, the rates were nearly identical between Farxiga and placebo (2.5% vs. 2.4%), suggesting the risk is low over time. Still, people with reduced kidney function, older adults, and anyone already taking a loop diuretic face higher risk and should watch for signs like dizziness, lightheadedness, or feeling unusually thirsty.
Why Farxiga Gets Combined With Real Diuretics
Farxiga is FDA-approved to reduce the risk of hospitalization and cardiovascular death in adults with heart failure, to slow kidney disease progression, and to lower cardiovascular risk in people with type 2 diabetes. Many of these patients are already on loop diuretics like furosemide.
Adding Farxiga to a loop diuretic often allows the diuretic dose to come down. In one study, patients on a median furosemide-equivalent dose of 20 mg per day when they started dapagliflozin were able to cut that dose in half to 10 mg per day after six months. No patients in the study had to stop the SGLT2 inhibitor because of side effects like low blood pressure. The takeaway: Farxiga can complement a diuretic and potentially reduce dependence on it, but it’s not meant to replace one.
The Bottom Line on Classification
Farxiga is an SGLT2 inhibitor, not a diuretic. It causes osmotic diuresis as a byproduct of dumping glucose into the urine, but this effect is milder than what you’d get from a traditional water pill and works through an entirely different pathway. Your body partially compensates for the extra fluid loss, so the net increase in urine volume is modest. The drug is prescribed primarily for heart failure, chronic kidney disease, and cardiovascular risk reduction in type 2 diabetes, not for fluid removal on its own.